Invivyd, Inc. (NASDAQ:IVVD) Director Sells $30,718.73 in Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 65,359 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $0.47, for a total value of $30,718.73. Following the transaction, the director now owns 4,012,320 shares in the company, valued at approximately $1,885,790.40. This trade represents a 1.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Terrance Mcguire also recently made the following trade(s):

• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Price Performance

Shares of Invivyd stock opened at $0.49 on Wednesday. The company’s 50 day moving average price is $0.81 and its two-hundred day moving average price is $1.04. The firm has a market capitalization of $58.61 million, a P/E ratio of -0.25 and a beta of 0.53. Invivyd, Inc. has a fifty-two week low of $0.45 and a fifty-two week high of $5.20.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. State Street Corp grew its position in Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after purchasing an additional 31,992 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Invivyd by 232.0% during the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after purchasing an additional 474,301 shares during the last quarter. Duquesne Family Office LLC acquired a new position in shares of Invivyd in the second quarter valued at approximately $629,000. Finally, Renaissance Technologies LLC bought a new position in Invivyd in the 2nd quarter valued at approximately $421,000. 70.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IVVD has been the subject of several analyst reports. D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Invivyd in a research report on Thursday, November 21st. Morgan Stanley cut their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, HC Wainwright dropped their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Invivyd currently has a consensus rating of “Buy” and a consensus target price of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.